Physician profile
Xiaochen Yang
NPI 1467178954
$11,041.42
in general payments reported to CMS, 2019-2025
23 companies · $5,366 in 2025
The $5,366 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,811 · 2024: $3,865 · 2025: $5,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,566.67 |
| Education | $474.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,510.84 | 2023-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $1,077.58 | 2023-2025 | Dupixent |
| Genzyme Corporation | $1,004.70 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $807.17 | 2024-2025 | Zoryve |
| Janssen Biotech, INC. | $797.37 | 2024-2025 | Tremfya |
| Abbvie INC. | $782.45 | 2023-2025 | |
| Leo Pharma INC. | $660.73 | 2025 | Adbry, Anzupgo |
| Pfizer INC. | $631.04 | 2023-2025 | |
| Dermavant Sciences, INC. | $580.92 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $498.81 | 2024-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $446.16 | 2024-2025 | |
| Lilly USA, LLC | $385.95 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Organon LLC | $309.73 | 2025 | Vtama, Nexplanon |
| Sun Pharmaceutical Industries INC. | $293.82 | 2023 | Ilumya, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $288.29 | 2023-2025 | Sotyktu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $191.88 | 2023-2025 | Cabtreo, Jublia, Arazlo |
| Ucb, INC. | $187.11 | 2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $151.32 | 2023 | |
| Botanix Sb INC | $143.04 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $106.05 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Sanofi US Services INC. | $70.11 | 2024-2025 | |
| Lnhc, INC | $21.36 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaochen Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.